PTPI OTC
Petros Pharmaceuticals, Inc.
1W: -6.2%
1M: -20.2%
3M: -23.5%
YTD: -53.1%
1Y: -85.0%
3Y: -100.0%
5Y: -100.0%
$0.00
+0.00 (+13.64%)
Weekly Expected Move ±50.8%
$-0
$0
$0
$0
$0
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Revenue Segmentation
By Product / Service
By Geography
Revenue by Segment (5-Year Trend)
Income Trends
Revenue
$5M
-12.2% ▼
5Y CAGR: -20.0%
Gross Profit
$4M
-7.0% ▼
5Y CAGR: +6.4%
Operating Income
-$18M
-29.8% ▼
Net Income
-$14M
-75.4% ▼
EPS (Diluted)
$-3.34
+47.4% ▲
EBITDA
-$11M
-156.8% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $10M | $8M | $6M | $6M | $5M |
| YoY Growth | -38.6% | -18.3% | -23.3% | -2.8% | -12.2% |
| Cost of Revenue | $4M | $2M | $2M | $2M | $1M |
| Gross Profit | $6M | $6M | $4M | $4M | $4M |
| Gross Margin | 57.7% | 79.5% | 61.8% | 72.0% | 76.3% |
| R&D Expenses | $460K | $2M | $2M | $2M | $3M |
| SG&A Expenses | $16M | $16M | $12M | $9M | $9M |
| Operating Expenses | $23M | $24M | $24M | $18M | $22M |
| Operating Income | -$17M | -$18M | -$20M | -$14M | -$18M |
| Operating Margin | -180.8% | -231.1% | -332.4% | -233.9% | -345.8% |
| Interest Expense | $3M | $369K | $596K | $536K | $561K |
| Income Before Tax | -$22M | -$9M | -$20M | -$8M | -$14M |
| Tax Expense | -$1M | $0 | $0 | $0 | $0 |
| Net Income | -$21M | -$9M | -$20M | -$8M | -$14M |
| Net Margin | -215.3% | -115.0% | -334.4% | -140.2% | -280.1% |
| EPS (Diluted) | $-38.55 | $-8.25 | $-9.68 | $-6.35 | $-3.34 |
| EBITDA | -$12M | -$2M | -$14M | -$4M | -$11M |
| Shares Outstanding | 534068 | 1M | 2M | 2M | 8M |